Receptors and Cellular Signaling Transduction Mechanics

Fundamentals of Signal Transduction and Receptor Theory

• Definition of Signal Transduction:
  • Signal transduction is the pathway of events by which each component participates in transmitting a neurotransmitter, hormonal, or growth factor signal to target molecules within the cell.
  • The general pathway proceeds sequentially:     $\text{Physiological Ligands / Drugs / Toxins} \rightarrow \text{Membrane or Cytosolic/Nuclear Receptor} \rightarrow \text{Signal Mediator} \rightarrow \text{Target Molecule} \rightarrow \text{Cellular Response}$

• Receptor Theory and Foundations:

  • The existence of biological receptors was first deduced from the observed specificity of cell and organ responses to both physiological and non-physiological chemicals.
  • Receptors have been isolated, biochemically characterized, and the genes encoding receptor proteins have been cloned, sequenced, and expressed.
  • Receptor theory accounts for the quantitative relationship between concentrations of an endogenous transmitter (ligand) or drug, the magnitude, and the type of physiological effects produced.
  • Receptors are responsible for the selectivity of transmitter action and mediate the actions of pharmacologic agents:
  • Agonists: Chemicals that enhance ongoing cellular function.
  • Antagonists: Chemicals that reduce ongoing cellular function.

• Features of Ligand-Receptor Interactions:

  • Endogenous transmitters physically interact with biological receptors to activate them and influence ongoing cellular functions, acting as agonists or allosteric modifiers.
  • Key characteristics of receptor-ligand interactions include:
  • Stringent structure-activity relationship (chemical specificity).
  • High degree of biological selectivity.
  • Discrete tissue distribution.
  • Activation of a finite number of receptors.
  • Reversibility of binding.
  • Overview flow of signaling:     $\text{Receptor} + \text{Transmitter} \rightarrow \text{Signal} \rightarrow \text{Signal Transduction} \rightarrow \text{Signal Integration} \rightarrow \text{Cellular Response}$

Classification and Characteristics of Signaling Ligands

• Properties of Chemical Ligands:

  • Ligands are secreted molecules, typically with a molecular weight of less than $1000\,\text{MW}$.
  • The chemical structure of a ligand dictates its likely signaling mechanism and the structural location of its receptor.

• Water-Soluble (Hydrophilic) Ligands:

  • Cannot freely cross the hydrophobic plasma membrane lipid bilayer.
  • Bind to cell-surface (extracellular) receptors to initiate intracellular signaling cascades.
  • Primary Examples:
  • Glutamate
  • Epinephrine / Norepinephrine
  • 5-HT (Serotonin)
  • Acetylcholine
  • Glucagon
  • Insulin

• Lipid-Soluble (Hydrophobic) Ligands:

  • Easily diffuse through the hydrophobic lipid bilayer of the plasma membrane.
  • Bind to intracellular receptors located in the cytoplasm or nucleus.
  • Primary Examples:
  • Estrogens (e.g., Estradiol)
  • Thyroid hormones (e.g., Thyroxine)
  • Glucocorticoids (e.g., Cortisol)
  • Testosterone
  • Retinoic acid
  • Vitamin $D_3$

Modes of Intercellular Communication

• Classification by Range and Signal Distribution:

• Direct Contact ("Juxtacrine") Signaling:

  • Requires direct physical contact between plasma-membrane-bound molecules on adjacent cells.
  • Example: Immune recognition in T lymphocytes, where a T cell receptor (TCR) and CD8 co-receptor interact directly with a peptide antigen presented on Major Histocompatibility Complex class I (MHC I) on a target cell.

• Paracrine Signaling:
  • Operates over short distances.
  • Involves short-lived signals (lasting seconds to minutes).
  • Released local mediators diffuse through extracellular fluid to affect nearby target cells.

• Autocrine Signaling:
  • A cell secretes a chemical signal that binds to membrane or cytosolic receptors on the same cell, signaling itself.
  • Primary Examples: Cytokines in immune cells, autocrine growth factors promoting cell division.

• Synaptic Signaling:
  • Specialized short-range chemical communication performed over long physical distances in animals via neuronal axons.
  • Nerve cells release neurotransmitters across a narrow chemical synapse / synaptic gap to target cells.
  • Characteristics:
  • Extremely fast (duration in milliseconds, $\text{msec}$).
  • High cell-to-cell specificity.
  • Strict signaling directionality (presynaptic cell to postsynaptic cell).

• Endocrine Signaling:
  • Chemical signals (hormones) are secreted into the bloodstream for wide dissemination throughout the body.
  • Hormones are typically transported bound to specific carrier/transport proteins.
  • Kinetic Profile: Slow on – slow off (effects persist over seconds to days).
  • Target specificity is limited strictly to "receptive" cells possessing specific cell-surface or intracellular receptors for the circulating hormone.

Receptor Kinetics and Receptor vs Enzyme Models

• Comparison of Enzyme and Receptors (Excitability Proteins):

• Enzyme Catalytic Model:   $[E] + [S] \underset{k_2}{\overset{k_1}{\rightleftharpoons}} [ES] \underset{k_4}{\overset{k_3}{\rightleftharpoons}} [E] + [P]$

• Receptor Excitability Protein Model:   $[L] + [R] \underset{k_{-1}}{\overset{k_{+1}}{\rightleftharpoons}} [LR] \overset{\alpha}{\rightarrow} [LR^{**}] \rightarrow \rightarrow \rightarrow \text{Cellular Response}$

• Kinetic Parameters for Receptors:

  • Equilibrium Dissociation Constant ($K_D$):     $K_D = \frac{k_{-1}}{k_{+1}}$
  • Measures receptor affinity and drug potency. A lower $K_D$ indicates higher affinity between ligand and receptor.
  • Intrinsic Efficacy ($\alpha$):
  • Measures the capacity of the bound ligand-receptor complex ($[LR]$) to convert into the active state ($[LR^{**}]$) and trigger downstream biological responses.

G-Protein Coupled Receptors (GPCRs) Structure and Activation Mechanism

• General Structural Topology of GPCRs:
  • Possess 7-transmembrane helices ($7\,\alpha$-helical domains spanning the plasma membrane lipid bilayer 7 times).
  • Extracellular domain contains an $\text{NH}_3^+$ terminus and forms the signal/ligand-binding site.
  • Intracellular domain contains a $\text{COO}^-$ terminus and extensive cytosolic loops that physically interact with heterotrimeric G-proteins ($\alpha, \beta, \gamma$ subunits).
  • Ligand binding in the extracellular site drives conformational changes across the transmembrane domains.

• GPCR Functional Activation Cycle:
  • Resting State (Inactive):
  • GPCR is unbound to ligand.
  • Heterotrimeric G-protein complex is inactive: $\text{G}_\alpha$ subunit is bound to GDP and associated with the $\text{G}_{\beta\gamma}$ dimer.
  • Effector enzyme that generates second messengers has low or zero baseline activity.
  • Activation Phase:
  • Agonist ligand (transmitter) binds to the extracellular pocket of the GPCR.
  • Conformational change in GPCR increases affinity for the $\text{G}_\alpha$ subunit.
  • Unbinding/displacement of GDP and binding of GTP onto $\text{G}_\alpha$ ($\text{G}_\alpha\text{-GDP} \rightarrow \text{G}_\alpha\text{-GTP}$).
  • $\text{G}_\alpha\text{-GTP}$ dissociates from the $\text{G}_{\beta\gamma}$ dimer.
  • $\text{G}_\alpha\text{-GTP}$ (and in some pathways, free $\text{G}_{\beta\gamma}$) binds to effector enzymes to stimulate or inhibit second messenger production.
  • Termination / Shutting Down Phase:
  • Ligand-bound GPCR is phosphorylated and desensitized/internalized.
  • Ligand dissociates from the receptor.
  • $\text{G}_\alpha$ subunit hydrolyzes bound GTP to GDP via intrinsic GTPase activity ($\text{G}_\alpha\text{-GTP} \rightarrow \text{G}_\alpha\text{-GDP} + P_i$).
  • $\text{G}_\alpha\text{-GDP}$ reassociates with the $\text{G}_{\beta\gamma}$ dimer to reform the inactive heterotrimer.
  • Second messenger production declines, returning the cell to rest.

Major GPCR Second Messenger Signaling Pathways

• Four Primary Intracellular Second Messengers:

  1. Cyclic AMP (cAMP, 3',5'-adenosine monophosphate)
  2. Inositol 1,4,5-trisphosphate ($\text{IP}_3$) / Calcium ($\text{Ca}^{2+}$)
  3. Diacylglycerol (DAG)
  4. Cyclic guanosine monophosphate (cGMP)

• Stimulatory vs. Inhibitory Adenylyl Cyclase (AC) Signaling:

  • Stimulatory Pathway ($R_s$ / $\text{G}_{\alpha s}$):
  • Ligand binds stimulatory GPCR ($R_s$).
  • Activates $\text{G}_{\alpha s}$, exchanging GDP for GTP.
  • $\text{G}_{\alpha s}\text{-GTP}$ stimulates Adenylyl Cyclase (AC).
  • AC converts ATP to cyclic AMP ($4\,\text{ATP} \rightarrow 4\,\text{cAMP}$).
  • Elevated cAMP activates Protein Kinase A (PKA).
  • PKA Activation Mechanism:
  • Inactive PKA exists as a tetramer containing 2 regulatory subunits and 2 inactive catalytic subunits.
  • Binding of 4 cAMP molecules to the regulatory subunits induces a conformational change, dissociating the complex and releasing 2 active catalytic subunits that phosphorylate specific target proteins.
  • Inhibitory Pathway ($R_i$ / $\text{G}_{\alpha i}$):
  • Ligand binds inhibitory GPCR ($R_i$).
  • Activates $\text{G}_{\alpha i}\text{-GTP}$, which directly inhibits Adenylyl Cyclase (AC).
  • Intracellular cAMP levels drop, leading to decreased PKA activity.

• Specific GPCR Pathway Examples:

• Example 1: $\beta$-Adrenergic Receptor Pathway

  • Ligands: Epinephrine, Norepinephrine.
  • GPCR: $\beta$-Adrenoreceptor ($\beta_1, \beta_2, \beta_3$).
  • Coupling: $\text{G}_{\alpha s}$ subunit.
  • Effector: Stimulates Adenylyl Cyclase (AC).
  • Second Messenger: Increases cAMP, activating Protein Kinase A (PKA).

• Example 2: Phospholipase C-$\beta$ / $\text{IP}_3$ / DAG / $\text{Ca}^{2+}$ Pathway

  • Ligand: Epinephrine, Norepinephrine binding $\alpha_1$-Adrenoreceptor ($\alpha_1$-AR).
  • Coupling: $\text{G}_{\alpha q}$ subunit.
  • Effector: Stimulates Phospholipase C-$\beta$ (PLC$\beta$).
  • Substrate Cleavage: PLC$\beta$ cleaves plasma membrane Phosphatidylinositol 4,5-bisphosphate ($\text{PIP}_2$) into two distinct second messengers:
  1. Inositol 1,4,5-trisphosphate ($\text{IP}_3$): Water-soluble lipid metabolite that diffuses through the cytosol and binds $\text{IP}_3$ receptors ($\text{IP}_3\text{R}$) on the endoplasmic/sarcoplasmic reticulum (ER/SR), opening channels to release stored $\text{Ca}^{2+}$.
  2. Diacylglycerol (DAG): Lipophilic product that remains bound within the plasma membrane.
  • Protein Kinase C (PKC) Activation:
  • Cytosolic $\text{Ca}^{2+}$ and membrane-bound DAG co-activate Protein Kinase C (PKC).
  • Coordinated activation by $\text{Ca}^{2+}$ and DAG permits flexible and precise regulation of PKC, a multifunctional kinase.
  • Muscle Function: In smooth muscle, \alpha_1$-AR activation via \text{G}{\alpha q}$increases$\text{IP}_3$and$\text{Ca}^{2+}, inducing muscle contraction.\n\n\n\n\n\n- Example 3: \alpha_2-Adrenergic Receptor Signaling in Smooth Muscle & Sympathetic Nerves\n - Ligand: Norepinephrine (NE).\n - GPCR: \alpha_2$-Adrenoreceptor ($\alpha_2-AR).\n - Coupling: \text{G}{\alpha i} subunit.\n - Effector: Inhibits Adenylyl Cyclase (AC), decreasing cAMP levels.\n - Physiological Roles:\n - On smooth muscle: Acts alongside \alpha_1-AR to facilitate contraction.\n - On presynaptic sympathetic nerve terminals: Provides negative feedback inhibition (-) to decrease further release of Norepinephrine (NE).\n\n\n\n- Example 4: Phototransduction via Transducin (\text{G}_{\alpha t}) and cGMP-PDE6\n - Location: Rod photoreceptor cells in the retina.\n - Receptor: Rhodopsin (contains 11-cis retinal chromophore).\n - Dark Condition:\n - High resting levels of cGMP keep cGMP-gated \text{Na}^+/\text{Ca}^{2+} cation channels open in the rod cell membrane.\n - Continuous inward cation current (\text{Na}^+$and$\text{Ca}^{2+} entry balanced by $4\text{Na}^+/\text{K}^+,\text{Ca}^{2+} exchanger) keeps the rod cell depolarized.
  • Light Activation Condition:
  • Light photoisomerizes 11-cis retinal to trans-retinal, activating rhodopsin.
  • Activated rhodopsin activates the G-protein Transducin ($\text{G}_{\alpha t}$).
  • $\text{G}_{\alpha t}\text{-GTP}$ activates PDE6 (retinal 3',5'-cGMP phosphodiesterase).
  • Active PDE6 hydrolyzes cGMP to GMP.
  • Decreased cytosolic cGMP causes cGMP-gated cation channels to close.
  • Influx of $\text{Na}^+$ and $\text{Ca}^{2+}$ stops while efflux via exchangers continues, hyperpolarizing the rod cell membrane and transmitting nerve impulses to the central nervous system.

Receptor Tyrosine Kinases (RTKs) and Enzyme-Linked Receptors

• Structural Architecture of RTKs:

  • Transmembrane receptors containing a single transmembrane $\alpha$-helix.
  • Possess an extracellular signal-molecule binding site.
  • Possess an intracellular tyrosine-kinase region containing specific tyrosine (Tyr) residues.
  • RTKs typically mediate the actions of growth factors and peptide hormones.

• Activation Mechanism and Cascade:

  1. Inactive State: RTKs exist as inactive monomers in the plasma membrane.
  2. Ligand Binding & Dimerization: Binding of dimeric or multivalent signal molecules brings two receptor monomers together into an active dimer.
  3. Autophosphorylation: Receptor dimerization stimulates intrinsic tyrosine kinase activity, causing cross-autophosphorylation (trans-autophosphorylation) of specific tyrosine residues on the cytosolic domains using ATP ($\text{ATP} \rightarrow \text{ADP} + P_i$).
  4. Protein Docking: Phosphorylated tyrosines create specific docking sites for cytosolic adapter and effector proteins containing SH2 domains.
  5. Signal Cascades:
  • Ras-MAPK Pathway: Phosphorylated EGFR binds Grb2, which recruits SOS (a guanine nucleotide exchange factor) to convert inactive Ras-GDP to active Ras-GTP. Ras-GTP activates Raf, which activates MEK, which activates Erk / MAP Kinase. Erk translocates to the nucleus to regulate gene transcription promoting cell proliferation.
  • PI3K-Akt Pathway: Phosphorylated RTK recruits Phosphoinositide 3-kinase (PI3K) to activate Akt, promoting cell survival.

• Major Protein Ligands Acting via RTKs:

  1. Insulin
  2. Insulin-like Growth Factors (IGF-1 & IGF-2)
  3. Epidermal Growth Factor (EGF)
  4. Nerve Growth Factor (NGF)
  5. Platelet-Derived Growth Factor (PDGF)
  6. Fibroblast Growth Factor (FGF)
  7. Growth Hormone (GH)
  8. Transforming Growth Factor alpha (TGF-$\alpha$)

• Clinical Relevance of Tyrosine Kinase Inhibitors (TKIs) in Dogs and Cats:

  • Tyrosine Kinase Inhibitors block the ATP-binding or catalytic sites of specific RTKs to treat neoplasia.
  • Kinavet (Masitinib):
  • Targets: Kit, (PDGFR)
  • Tumor Types: Mast Cell Tumors (MCTs)
  • Species: Dogs
  • Gleevec (Imatinib):
  • Targets: Kit, Abl, PDGFR
  • Tumor Types: MCTs, sarcomas
  • Species: Dogs, Cats
  • Key Abbreviations: TKI = tyrosine kinase inhibitor; PDGFR = platelet-derived growth factor receptor; MCT = mast cell tumor.

Cytoplasmic and Nuclear Receptors

• Mechanism of Intracellular Hormone Signaling:

  • Lipophilic/hydrophobic hormones (e.g., steroids, thyroid hormones) circulate in the bloodstream bound to carrier proteins.
  • Hormones dissociate from carrier proteins and cross the plasma membrane of target cells via passive diffusion.
  • Receptors reside in the cytoplasm or nucleus.

• Activation and Transcriptional Cascade:

  1. Sequestration: In the absence of hormone, inactive intracellular receptors are bound to chaperone proteins, specifically Hsp90 (Heat Shock Protein 90).
  2. Ligand Binding: Hydrophobic hormone binds to the receptor's ligand-binding domain.
  3. Chaperone Dissociation: Hormone binding causes a conformational change that triggers the dissociation of Hsp90.
  4. Dimerization & Translocation: The receptor undergoes homodimerization and translocates into the nucleus (if initially cytosolic).
  5. DNA Binding: The active receptor dimer binds specific target DNA sequences termed Hormone Response Elements (HREs), such as the Estrogen Response Element (ERE).
  6. Coactivator Recruitment: Bound receptors recruit coactivators (CoA) to stimulate transcription of target genes into mRNA, leading to protein synthesis and specific cellular responses.

• Estrogen Receptor (ER) Signaling Example:

  • Estrogen receptors exist in two main isoforms: $\text{ER}_\alpha$ and $\text{ER}_\beta$.
  • Estradiol ($E_2$) enters the target cell and binds ER.
  • Hsp90 dissociates from ER.
  • ER undergoes conformational change and dimerization (forming an $\text{ER-ER}$ homodimer).
  • The dimerized ER complex binds to the Estrogen Response Element (ERE) on DNA, recruits coactivators (CoA), and activates target gene transcription.
  • Note: Estrogen also acts via a membrane-bound GPCR (GPER) in neuronal populations.

• Clinical Relevance in Veterinary and Human Medicine:
  • Mammary Tumors occur frequently in humans, dogs, and cats.
  • Estrogen binds and activates $\text{ER}_\alpha$ in the nucleus to drive tumor proliferation.
  • Selective Estrogen Receptor Modulators (SERMs) compete with estrogen to alter $\text{ER}_\alpha$ binding capacity and block transcriptional activation.
  • Clinical Examples of SERMs: Tamoxifen, Raloxifene, and Bazedoxifene.